Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-01-31

AUTHORS

Thomas S. Y. Chan, Tsan-Hei Luk, June S. M. Lau, Pek-Lan Khong, Yok-Lam Kwong

ABSTRACT

Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100–200 mg, every 3 weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300–800) milligrams. Three CR patients have continued to receive pembrolizumab for a median of 16 (14–25) cycles, remaining in CR for a median of 18 (9–18) months. One CR patient underwent autologous hematopoietic stem cell transplantation and has remained in CR for 9 months. Partial response (PR) was achieved in one patient (20%), after a cumulative dose of 400 mg. The overall response rate was therefore 100% (CR: 80%; PR: 20%). Toxicity was virtually absent, with only grade 1 diarrhea and eczema each observed in one patient. Low-dose pembrolizumab was highly efficacious, achieving responses with minimal toxicity and at much lower costs. More... »

PAGES

647-651

References to SciGraph publications

  • 2014-07-10. The tumour microenvironment in B cell lymphomas in NATURE REVIEWS CANCER
  • 2013-03-08. Molecular mechanisms of T cell co-stimulation and co-inhibition in NATURE REVIEWS IMMUNOLOGY
  • 2014-12-23. Clinical blockade of PD1 and LAG3 — potential mechanisms of action in NATURE REVIEWS IMMUNOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00277-017-2931-z

    DOI

    http://dx.doi.org/10.1007/s00277-017-2931-z

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1083395775

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28138786


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hodgkin Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Secondary Prevention", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China", 
              "id": "http://www.grid.ac/institutes/grid.415550.0", 
              "name": [
                "Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chan", 
            "givenName": "Thomas S. Y.", 
            "id": "sg:person.013304036752.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013304036752.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China", 
              "id": "http://www.grid.ac/institutes/grid.415499.4", 
              "name": [
                "Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Luk", 
            "givenName": "Tsan-Hei", 
            "id": "sg:person.015750607111.76", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015750607111.76"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China", 
              "id": "http://www.grid.ac/institutes/grid.415499.4", 
              "name": [
                "Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lau", 
            "givenName": "June S. M.", 
            "id": "sg:person.011514450252.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011514450252.68"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China", 
              "id": "http://www.grid.ac/institutes/grid.415550.0", 
              "name": [
                "Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Khong", 
            "givenName": "Pek-Lan", 
            "id": "sg:person.01040056637.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040056637.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China", 
              "id": "http://www.grid.ac/institutes/grid.415550.0", 
              "name": [
                "Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kwong", 
            "givenName": "Yok-Lam", 
            "id": "sg:person.01100514066.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100514066.14"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nri3790", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009414011", 
              "https://doi.org/10.1038/nri3790"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri3405", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048395367", 
              "https://doi.org/10.1038/nri3405"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3774", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047004125", 
              "https://doi.org/10.1038/nrc3774"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-01-31", 
        "datePublishedReg": "2017-01-31", 
        "description": "Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100\u00a0mg, range: 100\u2013200\u00a0mg, every 3\u00a0weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300\u2013800) milligrams. Three CR patients have continued to receive pembrolizumab for a median of 16 (14\u201325) cycles, remaining in CR for a median of 18 (9\u201318) months. One CR patient underwent autologous hematopoietic stem cell transplantation and has remained in CR for 9\u00a0months. Partial response (PR) was achieved in one patient (20%), after a cumulative dose of 400\u00a0mg. The overall response rate was therefore 100% (CR: 80%; PR: 20%). Toxicity was virtually absent, with only grade 1 diarrhea and eczema each observed in one patient. Low-dose pembrolizumab was highly efficacious, achieving responses with minimal toxicity and at much lower costs.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00277-017-2931-z", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1358129", 
            "issn": [
              "0939-5555", 
              "1432-0584"
            ], 
            "name": "Annals of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "96"
          }
        ], 
        "keywords": [
          "complete response", 
          "classical Hodgkin lymphoma", 
          "CR patients", 
          "partial response", 
          "Hodgkin's lymphoma", 
          "cumulative dose", 
          "autologous hematopoietic stem cell transplantation", 
          "hematopoietic stem cell transplantation", 
          "minimal toxicity", 
          "median cumulative dose", 
          "grade 1 diarrhea", 
          "refractory Hodgkin lymphoma", 
          "stem cell transplantation", 
          "overall response rate", 
          "refractory/", 
          "brentuximab vedotin", 
          "cell transplantation", 
          "patients", 
          "response rate", 
          "pembrolizumab", 
          "high efficacy", 
          "lymphoma", 
          "dose", 
          "months", 
          "median", 
          "toxicity", 
          "response", 
          "chemotherapy", 
          "diarrhea", 
          "transplantation", 
          "multiple lines", 
          "efficacy", 
          "milligrams", 
          "rate", 
          "lines", 
          "cycle", 
          "cost", 
          "low cost"
        ], 
        "name": "Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity", 
        "pagination": "647-651", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1083395775"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00277-017-2931-z"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28138786"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00277-017-2931-z", 
          "https://app.dimensions.ai/details/publication/pub.1083395775"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:01", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_726.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00277-017-2931-z"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-2931-z'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-2931-z'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-2931-z'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-2931-z'


     

    This table displays all metadata directly associated to this object as RDF triples.

    188 TRIPLES      21 PREDICATES      77 URIs      66 LITERALS      18 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00277-017-2931-z schema:about N06b3af5f497542e6b3acf077e2a1ebb6
    2 N2c2dbecd7d5a46be9218b990758516a0
    3 N38affd55c91e4b5c8e0733b83266c4d1
    4 N6d9e61ab56b648e19401d70422fdc1d8
    5 N75bd45fd0775494b9606c1ae64d5c0d6
    6 N8128053bcabe45b18db9b01866af02d5
    7 Nb2af8714600f49bcbaf6c3959329bd79
    8 Nd881e27429d34e4c8a1e8ef9c4bf66b2
    9 Ndd5cb08b3846464c9d4e799838ea4ba8
    10 Ne8fdd4a5fb294effa7dc12aa33141a1e
    11 Nfe2622b6cdce47cc8da35af1ec178c69
    12 anzsrc-for:11
    13 anzsrc-for:1112
    14 schema:author N531561f2f44449d8a10e2f68e9728661
    15 schema:citation sg:pub.10.1038/nrc3774
    16 sg:pub.10.1038/nri3405
    17 sg:pub.10.1038/nri3790
    18 schema:datePublished 2017-01-31
    19 schema:datePublishedReg 2017-01-31
    20 schema:description Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100–200 mg, every 3 weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300–800) milligrams. Three CR patients have continued to receive pembrolizumab for a median of 16 (14–25) cycles, remaining in CR for a median of 18 (9–18) months. One CR patient underwent autologous hematopoietic stem cell transplantation and has remained in CR for 9 months. Partial response (PR) was achieved in one patient (20%), after a cumulative dose of 400 mg. The overall response rate was therefore 100% (CR: 80%; PR: 20%). Toxicity was virtually absent, with only grade 1 diarrhea and eczema each observed in one patient. Low-dose pembrolizumab was highly efficacious, achieving responses with minimal toxicity and at much lower costs.
    21 schema:genre article
    22 schema:isAccessibleForFree false
    23 schema:isPartOf N34dcfd3ae0dc4e18b445f278b04a440c
    24 Nf3ac7b2f5c234a15ab49d9969cc72b9d
    25 sg:journal.1358129
    26 schema:keywords CR patients
    27 Hodgkin's lymphoma
    28 autologous hematopoietic stem cell transplantation
    29 brentuximab vedotin
    30 cell transplantation
    31 chemotherapy
    32 classical Hodgkin lymphoma
    33 complete response
    34 cost
    35 cumulative dose
    36 cycle
    37 diarrhea
    38 dose
    39 efficacy
    40 grade 1 diarrhea
    41 hematopoietic stem cell transplantation
    42 high efficacy
    43 lines
    44 low cost
    45 lymphoma
    46 median
    47 median cumulative dose
    48 milligrams
    49 minimal toxicity
    50 months
    51 multiple lines
    52 overall response rate
    53 partial response
    54 patients
    55 pembrolizumab
    56 rate
    57 refractory Hodgkin lymphoma
    58 refractory/
    59 response
    60 response rate
    61 stem cell transplantation
    62 toxicity
    63 transplantation
    64 schema:name Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity
    65 schema:pagination 647-651
    66 schema:productId N365c5fc983334e1da926f22a7752ba97
    67 N5ba76df274e24d1f9a0783faaac4c70d
    68 N81662f73f1e141288a6370f2b0bdee9a
    69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083395775
    70 https://doi.org/10.1007/s00277-017-2931-z
    71 schema:sdDatePublished 2022-11-24T21:01
    72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    73 schema:sdPublisher N2b8c0b7d393c42129df69e0396c1146e
    74 schema:url https://doi.org/10.1007/s00277-017-2931-z
    75 sgo:license sg:explorer/license/
    76 sgo:sdDataset articles
    77 rdf:type schema:ScholarlyArticle
    78 N06b3af5f497542e6b3acf077e2a1ebb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Male
    80 rdf:type schema:DefinedTerm
    81 N247f2fa74efd4d8198d16e2e13ace751 rdf:first sg:person.011514450252.68
    82 rdf:rest N424623e1929c44b5ad0e75d1bbd970ad
    83 N2b8c0b7d393c42129df69e0396c1146e schema:name Springer Nature - SN SciGraph project
    84 rdf:type schema:Organization
    85 N2c2dbecd7d5a46be9218b990758516a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Dose-Response Relationship, Drug
    87 rdf:type schema:DefinedTerm
    88 N33a1b6a60dae4fe4859a8bbee2bbaefb rdf:first sg:person.015750607111.76
    89 rdf:rest N247f2fa74efd4d8198d16e2e13ace751
    90 N34dcfd3ae0dc4e18b445f278b04a440c schema:issueNumber 4
    91 rdf:type schema:PublicationIssue
    92 N365c5fc983334e1da926f22a7752ba97 schema:name pubmed_id
    93 schema:value 28138786
    94 rdf:type schema:PropertyValue
    95 N38affd55c91e4b5c8e0733b83266c4d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Middle Aged
    97 rdf:type schema:DefinedTerm
    98 N40554dda645044fdb3d4595cd2ff0ad5 rdf:first sg:person.01100514066.14
    99 rdf:rest rdf:nil
    100 N424623e1929c44b5ad0e75d1bbd970ad rdf:first sg:person.01040056637.02
    101 rdf:rest N40554dda645044fdb3d4595cd2ff0ad5
    102 N531561f2f44449d8a10e2f68e9728661 rdf:first sg:person.013304036752.03
    103 rdf:rest N33a1b6a60dae4fe4859a8bbee2bbaefb
    104 N5ba76df274e24d1f9a0783faaac4c70d schema:name doi
    105 schema:value 10.1007/s00277-017-2931-z
    106 rdf:type schema:PropertyValue
    107 N6d9e61ab56b648e19401d70422fdc1d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Treatment Outcome
    109 rdf:type schema:DefinedTerm
    110 N75bd45fd0775494b9606c1ae64d5c0d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Antineoplastic Agents
    112 rdf:type schema:DefinedTerm
    113 N8128053bcabe45b18db9b01866af02d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Humans
    115 rdf:type schema:DefinedTerm
    116 N81662f73f1e141288a6370f2b0bdee9a schema:name dimensions_id
    117 schema:value pub.1083395775
    118 rdf:type schema:PropertyValue
    119 Nb2af8714600f49bcbaf6c3959329bd79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Secondary Prevention
    121 rdf:type schema:DefinedTerm
    122 Nd881e27429d34e4c8a1e8ef9c4bf66b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Hodgkin Disease
    124 rdf:type schema:DefinedTerm
    125 Ndd5cb08b3846464c9d4e799838ea4ba8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Female
    127 rdf:type schema:DefinedTerm
    128 Ne8fdd4a5fb294effa7dc12aa33141a1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Adult
    130 rdf:type schema:DefinedTerm
    131 Nf3ac7b2f5c234a15ab49d9969cc72b9d schema:volumeNumber 96
    132 rdf:type schema:PublicationVolume
    133 Nfe2622b6cdce47cc8da35af1ec178c69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Antibodies, Monoclonal, Humanized
    135 rdf:type schema:DefinedTerm
    136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    137 schema:name Medical and Health Sciences
    138 rdf:type schema:DefinedTerm
    139 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    140 schema:name Oncology and Carcinogenesis
    141 rdf:type schema:DefinedTerm
    142 sg:journal.1358129 schema:issn 0939-5555
    143 1432-0584
    144 schema:name Annals of Hematology
    145 schema:publisher Springer Nature
    146 rdf:type schema:Periodical
    147 sg:person.01040056637.02 schema:affiliation grid-institutes:grid.415550.0
    148 schema:familyName Khong
    149 schema:givenName Pek-Lan
    150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040056637.02
    151 rdf:type schema:Person
    152 sg:person.01100514066.14 schema:affiliation grid-institutes:grid.415550.0
    153 schema:familyName Kwong
    154 schema:givenName Yok-Lam
    155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100514066.14
    156 rdf:type schema:Person
    157 sg:person.011514450252.68 schema:affiliation grid-institutes:grid.415499.4
    158 schema:familyName Lau
    159 schema:givenName June S. M.
    160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011514450252.68
    161 rdf:type schema:Person
    162 sg:person.013304036752.03 schema:affiliation grid-institutes:grid.415550.0
    163 schema:familyName Chan
    164 schema:givenName Thomas S. Y.
    165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013304036752.03
    166 rdf:type schema:Person
    167 sg:person.015750607111.76 schema:affiliation grid-institutes:grid.415499.4
    168 schema:familyName Luk
    169 schema:givenName Tsan-Hei
    170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015750607111.76
    171 rdf:type schema:Person
    172 sg:pub.10.1038/nrc3774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047004125
    173 https://doi.org/10.1038/nrc3774
    174 rdf:type schema:CreativeWork
    175 sg:pub.10.1038/nri3405 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048395367
    176 https://doi.org/10.1038/nri3405
    177 rdf:type schema:CreativeWork
    178 sg:pub.10.1038/nri3790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009414011
    179 https://doi.org/10.1038/nri3790
    180 rdf:type schema:CreativeWork
    181 grid-institutes:grid.415499.4 schema:alternateName Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China
    182 schema:name Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China
    183 rdf:type schema:Organization
    184 grid-institutes:grid.415550.0 schema:alternateName Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China
    185 Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
    186 schema:name Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China
    187 Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
    188 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...